List of Excipients in Branded Drug ALOMIDE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Alcon Laboratories Inc	ALOMIDE	lodoxamide tromethamine	0065-0345	BENZALKONIUM CHLORIDE
Alcon Laboratories Inc	ALOMIDE	lodoxamide tromethamine	0065-0345	CITRIC ACID MONOHYDRATE
Alcon Laboratories Inc	ALOMIDE	lodoxamide tromethamine	0065-0345	EDETATE DISODIUM

ALOMIDE Excipient Strategy and Commercial Opportunities for Lodoxamide Ophthalmic Solution

Last updated: September 9, 2026

Alomide is a prescription ophthalmic solution containing lodoxamide tromethamine 0.1%, equivalent to lodoxamide 1 mg/mL. Its commercial opportunity is primarily generic substitution and formulation improvement rather than long-term branded exclusivity. The most attractive development paths are preservative-free unit-dose delivery, lower-irritancy multidose packaging, improved ocular comfort, and supply-chain differentiation.

The reference formulation uses a conventional aqueous ophthalmic system with hypromellose, mannitol, disodium edetate, sodium citrate, tromethamine, pH adjusters, benzalkonium chloride and purified water. Each excipient has a functional role in viscosity, tonicity, buffering, chelation, preservation or pH control. Any reformulation must preserve sterility, drug stability, ocular tolerability and bioequivalence where an abbreviated regulatory pathway is pursued.

What is Alomide and how is lodoxamide delivered?

Alomide is the brand name for lodoxamide tromethamine ophthalmic solution. Lodoxamide is a mast-cell stabilizer used for the temporary prevention of itching and discomfort associated with allergic conjunctivitis. The labeled strength is 0.1%, with dosing generally consisting of one or two drops in each affected eye four times daily in patients aged two years and older. Treatment may require several days before maximum benefit is observed. [1]

Attribute	Alomide reference product
Active ingredient	Lodoxamide tromethamine
Equivalent lodoxamide concentration	1 mg/mL
Dosage form	Sterile ophthalmic solution
Route	Topical ocular
Primary use	Allergic conjunctivitis
Typical dosing	One or two drops, four times daily
Patient population	Adults and pediatric patients aged two years and older
Preservative	Benzalkonium chloride
Key formulation risks	Precipitation, pH drift, preservative compatibility, ocular irritation

Lodoxamide is not a biologic. Biosimilar competition does not apply. The relevant competitive pathways are generic ophthalmic solutions, branded allergy drops, preservative-free products and combination allergy therapies.

Which excipients are used in Alomide ophthalmic solution?

The Alomide formulation uses a conventional buffered, preserved aqueous vehicle. The principal excipients and their commercial functions are set out below.

Excipient or component	Likely formulation function	Commercial and technical relevance
Hypromellose	Viscosity enhancement and ocular residence time	May improve comfort and reduce drainage, but excessive viscosity can blur vision or impair drop formation
Mannitol	Tonicity adjustment and stabilizing polyol	Supports isotonicity and may reduce crystallization risk
Disodium edetate	Chelating agent	Binds trace metals that can catalyze degradation and improves preservative performance
Sodium citrate	Buffer component	Controls pH and supports chemical stability
Tromethamine	Buffer and counterion system	Maintains pH and is associated with the lodoxamide tromethamine active ingredient
Hydrochloric acid and sodium hydroxide	pH adjustment	Used to establish the target pH during manufacture
Benzalkonium chloride	Antimicrobial preservative	Enables multidose packaging but creates ocular-surface tolerability and chronic-use concerns
Purified water	Vehicle	Must meet pharmaceutical water and microbiological specifications

The excipient strategy is functionally balanced. Hypromellose supplies modest viscosity, while mannitol manages tonicity without relying solely on sodium chloride. Disodium edetate reduces metal-catalyzed degradation and can increase benzalkonium chloride effectiveness. The buffer system maintains the pH range required for product stability and patient tolerability. [1]

What formulation patents protect Alomide and lodoxamide products?

The commercial protection for an older small-molecule ophthalmic product is usually less durable than the formulation-development opportunity. Alomide was approved under an NDA pathway, and any remaining U.S. exclusivity or patent protection must be evaluated through the current FDA Orange Book and relevant patent records. [2]

The most commercially relevant intellectual-property categories are:

1. Lodoxamide composition claims.
2. Lodoxamide tromethamine salt claims.
3. Ophthalmic solution claims covering concentration, pH, tonicity and excipient combinations.
4. Method-of-use claims for allergic conjunctivitis.
5. Container-closure and multidose delivery claims.
6. Preservative-free packaging claims.
7. Manufacturing methods for sterile filtration, filling and impurity control.

For a generic lodoxamide product, the primary competitive barrier is likely to be regulatory execution and commercial scale rather than a broad composition-of-matter patent. A developer should separate three questions:

• Whether an Orange Book-listed patent remains relevant.
• Whether the proposed product can qualify for an ANDA with an appropriate bioequivalence strategy.
• Whether a differentiated formulation requires a new NDA or a separate 505(b)(2) approach.

When does Alomide lose exclusivity and what is the generic entry risk?

Alomide is an older ophthalmic product, so the principal market risk is generic entry rather than biosimilar substitution. FDA generic applicants may pursue an ANDA when the proposed product has the same active ingredient, strength, dosage form, route and relevant performance characteristics as the reference listed drug.

Patent and exclusivity analysis should cover the following data points:

Exclusivity issue	Relevance to lodoxamide
New chemical entity exclusivity	Historical issue; unlikely to be the current commercial barrier for an older product
Pediatric exclusivity	Must be confirmed from FDA records
Orange Book patent listings	Determine whether a Paragraph IV certification is required
Paragraph IV litigation	Can delay approval or create a 30-month stay if statutory conditions are met
Formulation patents	May affect preservative-free, viscosity-modified or container-specific products
Method-of-use patents	Could constrain labeled allergic-conjunctivitis indications
Regulatory exclusivity for a reformulation	May support a 505(b)(2) strategy if clinically and technically justified

A generic launch can occur through several scenarios:

• Immediate launch after approval if no blocking patent or exclusivity remains.
• At-risk launch after Paragraph IV certification and litigation analysis.
• Delayed launch under a settlement agreement.
• Authorized or partnered launch using the reference product’s commercial infrastructure.
• Reformulated launch through a 505(b)(2) pathway.

The revenue impact depends on the number of approved competitors, reimbursement placement, retail availability and substitution rules. Ophthalmic generics can lose price rapidly after multiple entrants, while preservative-free or device-differentiated products may retain a premium.

What preservative-free opportunities exist for Alomide?

The clearest formulation opportunity is a preservative-free lodoxamide product. Benzalkonium chloride is effective and familiar, but repeated exposure can damage the ocular-surface epithelium, particularly in patients with dry eye, chronic allergic disease or frequent dosing requirements. [3]

A preservative-free product could use:

• Single-dose polyethylene ampoules.
• Blow-fill-seal unit-dose containers.
• Multidose systems with sterilizing air filters or one-way valves.
• Proprietary closure systems that prevent microbial ingress.
• Low-extractables polymer containers with controlled drop size.

The unit-dose approach is technically straightforward but increases packaging cost, fill-finish complexity, transport volume and waste. A preservative-free multidose system has greater commercial value but creates a more demanding container-closure and antimicrobial protection package.

The principal development risks are microbial ingress, extractables and leachables, container adsorption, delivered-dose variability and patient handling. FDA ophthalmic products must comply with sterility, particulate, container-closure integrity and stability requirements. [4]

How can excipients improve ocular comfort and product differentiation?

Lodoxamide does not require an elaborate delivery system. The highest-value formulation changes are likely to be incremental.

Hypromellose optimization

Hypromellose can increase residence time and reduce immediate drainage. A higher viscosity may support longer contact with the ocular surface, but excessive viscosity can cause transient blur, stringing or inconsistent drop size. A developer should optimize viscosity at the point of administration rather than maximize it.

Buffer reduction

A lower-buffer-capacity formulation may improve comfort when the product encounters tears with a different pH. Buffer selection also affects the free-base and salt balance of lodoxamide, chemical stability and preservative activity. Reducing buffer concentration can improve tolerability but may increase pH drift during storage.

Alternative tonicity systems

Mannitol is already a useful tonicity agent. Sodium chloride, glycerol or other polyols could be evaluated, but substitution must be assessed for osmolality, comfort, degradation, crystallization and drop evaporation. The objective is a physiologically acceptable osmolality without creating precipitation or viscosity problems.

Preservative alternatives

A preservative-free product is generally more commercially differentiated than a product that replaces benzalkonium chloride with another preservative. Polyquaternium-1, stabilized oxychloro complex and other preservative systems may reduce some ocular-surface concerns, but they do not eliminate preservative-related tolerability, regulatory and compatibility work.

Chelation strategy

Disodium edetate can improve stability and preservative performance by controlling trace metals. Removing it may simplify the label but can increase oxidation or reduce antimicrobial robustness. Its concentration should be optimized against impurity formation, preservative efficacy and container compatibility.

What manufacturing and intellectual-property barriers affect lodoxamide products?

The manufacturing process is relatively conventional but not trivial. The key controls are:

1. Dissolution order for lodoxamide tromethamine and excipients.
2. Control of pH before and after sterilizing filtration.
3. Prevention of precipitation during bulk hold and filling.
4. Low bioburden and validated sterile filtration.
5. Container-closure integrity.
6. Control of particulate matter.
7. Consistent drop size and delivered volume.
8. Stability under temperature and light stress.

An improved product can generate protectable intellectual property through a narrow combination of active ingredient, pH range, osmolality, viscosity, preservative level, container material and delivery performance. Patent strength is higher when the formulation produces a measured technical effect, such as improved stability, reduced impurity growth, longer ocular residence time or lower preservative exposure.

Weak patent positions generally rely on routine excipient substitutions without an unexpected result. Stronger claims would link a defined excipient range to a specific stability, tolerability or delivery outcome.

How does Alomide compare with competing allergy eye drops?

Lodoxamide competes with several classes of ophthalmic allergy products.

Product category	Examples	Commercial positioning
Mast-cell stabilizers	Lodoxamide, cromolyn	Preventive use; often require repeated dosing
Dual-action antihistamine/mast-cell stabilizers	Olopatadine, ketotifen, azelastine	Stronger convenience proposition and broad retail presence
Antihistamines	Various prescription and OTC products	Rapid symptom relief
Corticosteroids	Loteprednol and others	More potent anti-inflammatory activity but greater safety constraints
Artificial tears and lubricants	Carboxymethylcellulose, hypromellose products	Supportive care and ocular-surface relief

Alomide’s four-times-daily dosing is a commercial disadvantage against once- or twice-daily products. A preservative-free presentation could offset part of that disadvantage in patients with chronic exposure, ocular-surface disease or contact-lens-related sensitivity.

What FDA regulatory pathway is most attractive?

A conventional generic lodoxamide ophthalmic solution would normally be evaluated under the ANDA framework if the reference-product and bioequivalence requirements can be met. FDA product-specific guidance, where available, should control the development design. [5]

A differentiated product may require a 505(b)(2) NDA if it introduces:

• A new preservative-free delivery system.
• A materially different formulation.
• A new dosage regimen.
• A new indication.
• A novel container or device with clinically relevant performance.
• A change that cannot be supported solely by reference-product equivalence.

The regulatory strategy should be selected before formulation lock. An ANDA favors close formulation and product similarity. A 505(b)(2) program permits more differentiation but increases clinical, regulatory and intellectual-property costs.

Which commercial opportunities are most attractive?

The strongest opportunities are ranked below.

Opportunity	Technical complexity	Differentiation	Commercial potential
Standard generic preserved solution	Low to moderate	Low	High only with efficient scale and distribution
Preservative-free unit-dose solution	Moderate	High	Attractive in chronic-use and sensitive-eye segments
Preservative-free multidose product	High	Very high	Potential premium and stronger brand defense
Lower-viscosity comfort formulation	Moderate	Moderate	Useful if comfort and drop consistency improve
Higher-viscosity residence-time formulation	Moderate	Moderate	Limited by blur and patient acceptance
Combination product	High	High	Requires stronger clinical and regulatory investment
Device-led delivery system	High	High	Can support differentiated pricing and patent claims

Licensing opportunities may include an established ophthalmic manufacturer, a preservative-free packaging company, a contract sterile-fill partner or a branded generic platform. The most valuable deal structure would combine formulation IP with validated container technology and commercial access to ophthalmology channels.

What patent litigation and settlement issues affect Alomide?

Paragraph IV litigation is relevant only if a current Orange Book-listed patent creates a barrier to approval or launch. A generic applicant may certify that a listed patent is invalid, unenforceable or not infringed. The NDA holder can file suit within the statutory period, potentially triggering a 30-month stay of approval. [6]

A settlement could provide:

• A fixed generic entry date.
• A license to launch before patent expiry.
• An authorized generic arrangement.
• Restrictions on formulation or indication.
• Supply or distribution rights.
• A covenant governing future patent enforcement.

For an older ophthalmic product, the probability of a commercially important settlement depends on current patent listings, market size, number of applicants and the strength of any formulation or use claims. The most relevant diligence targets are current Orange Book entries, FDA approval history, ANDA approvals, federal docket records and product availability data.

Key Takeaways

• Alomide contains lodoxamide tromethamine 0.1% in a buffered, preserved aqueous ophthalmic solution.
• Hypromellose, mannitol, disodium edetate, citrate, tromethamine and benzalkonium chloride each perform defined formulation functions.
• Biosimilar risk does not apply because lodoxamide is a small molecule.
• Generic substitution is the principal market risk for the reference product.
• Preservative-free unit-dose and multidose presentations offer the clearest commercial differentiation.
• A multidose preservative-free product has greater value but requires substantial container-closure and microbiological validation.
• A standard generic is likely to compete primarily on cost, supply reliability and pharmacy access.
• A 505(b)(2) pathway may be appropriate for materially differentiated delivery, preservative or dosing systems.
• Patent strength will depend on demonstrated technical effects rather than routine excipient substitution.
• The relevant litigation risks are Orange Book patents, Paragraph IV certifications and settlement-controlled launch timing.

FAQs About Alomide Excipient Strategy

Is Alomide preservative-free?

No. The conventional Alomide ophthalmic solution contains benzalkonium chloride as a preservative. A preservative-free version would require different packaging and a separate stability and microbiological-control strategy. [1]

Can benzalkonium chloride be removed from a lodoxamide formulation?

Yes, but removal requires a preservative-free container system or an alternative antimicrobial strategy. The change can affect sterility assurance, stability, container compatibility and the applicable regulatory pathway.

Is lodoxamide a good candidate for a generic ophthalmic product?

Yes, provided the developer can establish pharmaceutical equivalence, product quality, sterility and the required bioequivalence or comparative-performance evidence. Market attractiveness depends on competitor count and reimbursement conditions.

Which excipient is most important for Alomide ocular residence time?

Hypromellose is the principal excipient associated with increased viscosity and ocular residence time. Its concentration must be balanced against transient blurred vision, drop-size consistency and patient comfort.

Does a reformulated Alomide product need new clinical trials?

A conventional generic may rely on an ANDA pathway and comparative evidence. A materially different formulation, delivery system, indication or dosing regimen may require a 505(b)(2) application and additional clinical or pharmacology support.

References

1. U.S. Food and Drug Administration. (n.d.). Alomide (lodoxamide tromethamine ophthalmic solution) prescribing information.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. Baudouin, C., Labbe, A., Liang, H., Pauly, A., & Brignole-Baudouin, F. (2010). Preservatives in eyedrops: The good, the bad and the ugly. Progress in Retinal and Eye Research, 29(4), 312-334.
4. U.S. Food and Drug Administration. (2008). Guidance for industry: Sterile drug products produced by aseptic processing: Current good manufacturing practice.
5. U.S. Food and Drug Administration. (n.d.). Product-specific guidances for generic drug development.
6. U.S. Food and Drug Administration. (2017). ANDA submissions: Refuse-to-receive standards.